An Adaptive Two-Stage Dose-Response Design Method for Establishing Proof of Concept

By Franchetti Yoko   Anderson Stewart J.   Sampson Allan R.  

Journal of Biopharmaceutical Statistics, Vol. 23, Iss. 5, 2013-09 ,pp. : 1124-1154

Taylor & Francis Ltd

Access to resources Recommend Favorite

The orexin-OX1/OX2 receptor antagonist ACT 078573 has met its proof-of-concept primary endpoint in primary insomnia.

By  

Inpharma, Vol. 1, Iss. 1575, 2007-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Application of Clinical Trial Simulation to Compare Proof-of-Concept Study Designs for Drugs with a Slow Onset of Effect; An Example in Alzheimer's Disease

By Lockwood Peter   Ewy Wayne   Hermann David   Holford Nick  

Pharmaceutical Research, Vol. 23, Iss. 9, 2006-09 ,pp. : 2050-2059

Springer Publishing Company

Access to resources Recommend Favorite

In mononeuropathic rats, the enhancement of morphine antinociception by L-365,260, a selective CCK B receptor antagonist, depends on the dose of systemic morphine and stimulus characteristics

By Idanpaan-Heikkila J.J.   Perrot S.   Guilbaud G.   Kayser V.  

European Journal of Pharmacology, Vol. 325, Iss. 2, 1997-05 ,pp. : 155-164

Elsevier

Access to resources Recommend Favorite

FAUC 213, a highly selective dopamine D₄ receptor full antagonist, exhibits atypical antipsychotic properties in behavioural and neurochemical models of schizophrenia

By Boeckler Frank   Russig Holger   Zhang Weining   Löber Stefan   Schetz John   Hübner Harald   Ferger Boris   Gmeiner Peter   Feldon Joram  

Psychopharmacology, Vol. 175, Iss. 1, 2004-08 ,pp. : 7-17

Springer Publishing Company

Access to resources Recommend Favorite